Clinical value of combined detection of serum anti-PLA2R-IgG antibody and its subtype anti-PLA2R-IgG4 antibody in idiopathic membranous nephropathy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300071315

Enrollment

Unknown

Registered

2023-05-11

Start date

2023-05-20

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic membranous nephropathy

Interventions

Gold Standard:Renal biopsy and serum markers

Index test:Methods: Time-resolved fluorescence immunoassay was used. Biomarkers were serum anti-PLA2R-IgG and anti-PLA2R-IgG4

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with idiopathic membranous nephropathy are diagnosed by renal puncture

Exclusion criteria

Exclusion criteria: Secondary membranous nephropathy and other primary glomerular diseases

Design outcomes

Primary

Measure	Time frame
anti-PLA2R-IgG and anti-PLA2R-IgG4;	—

Secondary

Measure	Time frame
specificity;sensitivity;	—

Countries

China

Contacts

Public ContactXuehen

Ya'an People's Hospital

445960797@qq.com+86 13551595279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026